

Nectar Lifesciences Ltd.



Ref No. NLL/CS/2015-265

Dated: 13.11.2015

1. National Stock Exchange of India Limited
Exchange Plaza, C-1, Block - G, Bandra Kurla Complex,
Bandra (East), MUMBAI – 400 051.
2. BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI – 400 001.

Sub: Compliance under Clause 41 the Listing Agreement.

Sirs,

Pursuant to Clause 41 of the Listing Agreement, please find enclosed herewith a copy of the Unaudited Financial Results for the period ended on September 30, 2015, as approved by the Board of Directors in their meeting held on even date i.e. November 13, 2015. A copy of the Limited Review Report is also enclosed herewith for your record please.

Kindly acknowledge receipt of the same and oblige.

Thanking you,

Yours faithfully,

For NECTAR LIFESCIENCES LIMITED

Sunder Lal
Company Secretary

Encl. as above

Corporate Office : S.C.O. 38-39, Sector 9-D, Chandigarh-160 009 (India) Tel. : +91-172-3047777 Fax : +91-172-3047755
E-mail : sales@necLife.com Website : www.necLife.com
CIN : L24232 PB1995 PLC 016664

Regd. Office & Works : Vill. Saidpura, Teh. Dera Bassi, Distt. Mohali (Punjab) Near Chandigarh (INDIA)
Tel. : +91-1762-308000, 308001 Fax : +91-1762-281187, 308135





NECTAR LIFESCIENCES LIMITED

Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. Mohali, (Punjab), Corporate Identification Number: L24232PB1995PLC016664


Tel. +91-17 62-30 8000, Fax +91-17 62-30 8135, Email : sunderlal@nectarlife.com, Website : www.nectarlife.com

Part I Statement of Unaudited Financial Results for the Quarter and Six Months ended 30.09.2015 (Rs in Lacs)

S. No	PARTICULARS	Quarter ended 30-09-15	Quarter ended 30-06-15	Quarter ended 30-09-14	Half Year ended 30-09-15	Half Year ended 30-09-14	Year ended 31-03-15
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Income from Operations						
	(a) Gross Sales	42,156.76	43,152.19	42,113.15	85,308.95	82,326.69	174,638.61
	Less : Excise Duty	2,490.18	2,383.51	2,739.58	4,873.69	4,795.33	10,349.72
	Net Sales	39,666.59	40,768.68	39,373.57	80,435.27	77,531.36	164,288.89
	(b) Other Operating Income	0.17	1.52	15.14	1.68	29.19	75.30
	Total Income from Operations (net)	39,666.75	40,770.20	39,388.71	80,436.95	77,560.55	164,364.19
2.	Expenses						
	(a) Cost of Materials consumed	25,583.76	26,469.33	24,794.12	52,053.09	50,110.26	112,990.38
	(b) Purchase of Stock in Trade	1,038.60	854.58	725.92	1,893.18	2,150.09	3,960.61
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(160.23)	290.36	1,043.70	130.13	902.14	(2,817.56)
	(d) Employee benefits expense	1,716.88	1,686.87	1,463.37	3,403.74	2,850.51	6,270.67
	(e) Depreciation and amortisation expense	2,194.06	2,178.71	1,887.72	4,372.77	3,810.98	7,656.43
	(f) Other expenses	4,128.26	4,413.68	4,129.75	8,541.94	7,742.05	17,269.38
	Total Expenses	34,501.33	35,893.53	34,044.58	70,394.85	67,566.03	145,329.91
3.	Profit from Operations before Other income, finance costs and exceptional Items (1-2)	5,165.42	4,876.67	5,344.13	10,042.10	9,994.52	19,034.28
4.	Other Income	127.02	126.71	266.31	253.73	496.54	1,999.88
5.	Profit before finance costs and exceptional Items (3+4)	5,292.44	5,003.39	5,610.44	10,295.83	10,491.06	21,034.16
6.	Finance costs	3,082.20	2,733.24	3,548.48	5,815.44	6,388.59	12,558.79
7.	Profit after finance costs but before exceptional Items (5-6)	2,210.24	2,270.14	2,061.96	4,480.39	4,102.47	8,475.37
8.	Exceptional Items	-	-	-	-	-	-
9.	Profit from ordinary activities before tax (7+8)	2,210.24	2,270.14	2,061.96	4,480.39	4,102.47	8,475.37
10.	Tax Expense	477.80	528.80	420.17	1,006.60	835.64	1,848.98
11.	Net Profit from ordinary activities after tax (9-10)	1,732.45	1,741.34	1,641.79	3,473.79	3,266.83	6,626.39
12.	Extraordinary Item (net of tax expense)	-	-	-	-	-	-
13.	Net Profit for the period (11-12)	1,732.45	1,741.34	1,641.79	3,473.79	3,266.83	6,626.39
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61
15.	Reserves excluding Revaluation Reserves	-	-	-	-	-	93,552.29
16.i	Earnings per Share (EPS) (before extraordinary items)						
	a) Basic	0.77	0.78	0.73	1.55	1.46	2.95
	b) Diluted	0.77	0.78	0.73	1.55	1.46	2.95
16.ii	Earnings per Share (EPS) (after extraordinary items)						
	a) Basic	0.77	0.78	0.73	1.55	1.46	2.95
	b) Diluted	0.77	0.78	0.73	1.55	1.46	2.95

Part II Select Information for the Quarter and six month ended 30.09.2015

A Particulars of shareholding							
1.	Public Shareholding						
	- Number of Shares	124,792,970	124,792,970	124,792,970	124,792,970	124,792,970	124,792,970
	- Percentage of Shareholding	55.65	55.65	55.65	55.65	55.65	55.65
2.	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	55,555,600	55,555,600	55,555,600	55,555,600	55,555,600	55,555,600
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	55.85	55.85	55.85	55.85	55.85	55.85
	- Percentage of Shares (as a % of the total share capital of the company)	24.77	24.77	24.77	24.77	24.77	24.77
	b) Non-encumbered						
	- Number of Shares	43,912,400	43,912,400	43,912,400	43,912,400	43,912,400	43,912,400
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	44.15	44.15	44.15	44.15	44.15	44.15
	- Percentage of Shares (as a % of the total share capital of the company)	19.58	19.58	19.58	19.58	19.58	19.58



B	Investor Complaints	3 Months ended 30.09.2015
	Pending at the beginning of Quarter	-
	Received During the Quarter	-
	Disposed Off During the Quarter	26
	Pending at the end of Quarter	26

Statement of Assets and Liabilities		(Rs in Lacs)	
PARTICULARS		As at	As at
		30-09-15	31-03-15
		Unaudited	Audited
SHAREHOLDERS' FUND			
(i) Capital			
(ii) Reserves and Surplus		2,242.61	2,242.61
NON CURRENT LIABILITIES		97,026.03	93,552.29
(i) Long Term Liabilities			
(ii) Deferred Tax Liability		28,027.46	26,552.92
(iii) Other Long Term Liabilities		11,726.07	11,019.28
(iv) Long Term Provisions		1,763.73	1,518.72
CURRENT LIABILITIES		664.40	601.13
(i) Short Term Borrowings			
(ii) Trade Payables		59,510.14	59,529.78
(iii) Other Current Liabilities		43,187.06	45,557.72
(iv) Short Term Provisions		11,751.38	9,050.00
		1,790.82	1,422.15
Total		257,689.70	251,046.60
NON CURRENT ASSETS			
(i) Fixed Assets (Incl CWIP)		102,078.18	102,504.37
(ii) Non Current Investments		5.01	5.01
(iii) Long Term Loans & Advances		8,263.30	8,044.27
(iv) Other Non Current Assets		5,324.79	3,591.24
CURRENT ASSETS			
(i) Current Investments			
(ii) Inventories		43.51	43.51
(iii) Trade Receivables		81,938.70	79,097.46
(iv) Cash & Bank Balances		43,736.79	44,649.64
(v) Short Term Loans & Advances		2,626.31	3,338.20
(vi) Other Current Assets		11,294.76	8,143.15
		2,378.35	1,629.75
Total		257,689.70	251,046.60

Notes:

- 1 The above financial results were reviewed by Audit Committee on 12.11.15 and approved by the Board in its meeting held on even date i.e. 13.11.15 and further limited reviewed by the Statutory Auditors of the Company.
- 2 The company is exclusively in the pharmaceutical business segment.
- 3 The Shareholders in their Annual General Meeting held on 30.09.2015 have declared the final dividend of Re. 0.10/- per equity share (10% on the face value of Re. 1/- per equity share) for the financial year 2014-15. The Company has despatched Dividend Warrants to the shareholders at their registered addresses, and wherever applicable, the Dividend has been credited to the shareholders' accounts directly through National Electronic Credit Settlement (NECS/ECS/NEFT/ Direct Credit) facility of RBI.
- 4 Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- 5 The above financial results are on stand alone basis.

By Order of the Board of Directors
of Nectar Lifesciences Limited

(Dinesh Dua)

Chief Executive Officer & Director

Dated: 13.11.15

Place: Chandigarh



DATTA SINGLA & CO.
Chartered Accountants

SCO 2935-36, Level 1, Sector 22-C,
Chandigarh - 160 022 (INDIA)
Tele : +91-172-2707065, 5086551 / 52
Fax : +91-172-5019550

To Whomsoever It May Concern

We have reviewed the accompanying statement of unaudited financial results of Nectar Lifesciences Limited for the quarter ended September 30, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards (which continue to be applicable in respect of Section 133 of the Companies Act, 2013 in terms of General Circular 15/2013 dated September 13, 2013 of the Ministry of Corporate Affairs) and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Datta Singla & Company
Chartered Accountants

Firm Regn. No. 006185N



Place: Chandigarh
Date: 13.11.2015